Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.

Dr. Christopher Schaber, President & CEO of Soligenix Inc. talks about the company’s activities.

Video provided courtesy of Thomson Reuters Insider Network

 
* * Latest News Latest News
 
* * Relevant Publications Publications
 
* * Presentations Presentations

Corporate Presentation
June 22, 2016
View the presentation (pdf)


SGX942 MASCC Presentation
June 25, 2016

View the presentation on YouTube

View the presentation (pdf)


Non Confidential Introduction to ThermoVax™
May 2015
View the presentation (pdf)

Partnering with Us

Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of oncology, supportive cancer care, gastrointestinal and biodefense.

Learn more >